# Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )

> **NCT03403140** · PHASE3 · UNKNOWN · sponsor: **Gema Biotech S.A.** · enrollment: 141 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT03403140
- **Lead sponsor:** Gema Biotech S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10-06
- **Primary completion:** 2018-09-30
- **Final completion:** 2018-10-31
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2018-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403140, "Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03403140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*